Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]
Nausea is actually considered an on target side effect of semaglutide because the nausea helps you to reduce your caloric intake and lose weight
In simple terms, the process looks like this: Eat more fibre Feed healthy gut bacteria Produce more SCFAs Increase natural GLP-1 release Feel full for longer
Yang Z, Tian R, Zhang XJ, Cai J, She ZG, Li H
Combined use may result in severe nausea that interferes with adequate nutrition and hydration